Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (&#34;CNS&#34; or the &#34;Company&#34;), a biotechnology company focused on building a pipeline of innovative

<p><i><strong>Access the CEO Connect segment </strong></i><a rel="nofollow" href="https://virtualinvestorco.com/cnsp/"><i><strong>here</strong></i></a></p> <p><strong id="dateline">HOUSTON, TX / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 20, 2026 / </strong>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CNSP">CNSP</a>) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a <a rel="nofollow" href="https://pr.report/lpm9">Virtual Investor CEO Connect Segment</a>.</p><p>As part of the segment, <a rel="nofollow" href="https://pr.report/lpma">Rami Levin, President and Chief Executive Officer</a> of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value. Additionally, Mr. Levin discussed the strategy for pipeline development and securing a new asset, key milestones investors should monitor to evaluate execution of the strategy and the Company's broader growth outlook and investment thesis moving forward.</p><p>The Virtual Investor CEO Connect segment is accessible <a rel="nofollow" href="https://pr.report/lpmb">here</a>.</p><p><strong>About CNS Pharmaceuticals, Inc.</strong></p><p>CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.</p><p>For more information, please visit <a rel="nofollow" href="https://pr.report/lpmc">www.CNSPharma.com</a>, and connect with the Company on <a rel="nofollow" href="https://pr.report/lpmd">X</a> and <a rel="nofollow" href="https://pr.report/lpme">LinkedIn</a>.</p><p><strong>Forward-Looking Statements</strong></p><p>Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.</p><p><strong>CONTACTS:</strong></p><p><strong>Investor Relations Contact</strong></p><p>JTC Team, LLC<br/>Jenene Thomas<br/>908.824.0775<br/><a rel="nofollow" href="mailto:CNSP@jtcir.com">CNSP@jtcir.com</a></p><p><strong>Business Development Contact</strong></p><p>CNS Pharmaceuticals, Inc.<br/>Dylan Wenke, Chief Business Officer<br/><a rel="nofollow" href="mailto:dwenke@cnspharma.com">dwenke@cnspharma.com</a></p><p><strong>SOURCE: </strong>CNS Pharmaceuticals, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cns-pharmaceuticals-ceo-rami-levin-participates-in-virtual-investor-c-1168479'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1168479" width="0" height="0"/>

CNSP

CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

CNS Pharmaceuticals Highlights Financing and Growth Strategy to Investors

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (&amp;#34;CNS&amp;#34; or the &amp;#34;Company&amp;#34;), a biotechnology company focused on building a pipeline of innovative</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>CNS Pharmaceuticals participated in an investor segment, showcasing a recent $22.5 million financing that will enable new asset development. The CEO highlighted strategic initiatives aimed at long-term shareholder value, urging investors to track upcoming milestones indicative of growth.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CNSP participated in a Virtual Investor CEO Connect segment on May 20, 2026.</li><li>CEO Rami Levin discussed a recent $22.5 million financing round.</li><li>CNSP aims to use the funds for new asset development.</li><li>The company is focused on addressing significant unmet medical needs.</li><li>Investors should monitor key milestones for future growth.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>CNS Pharmaceuticals, Inc. (CNSP)</strong>: Recent financing positions CNSP well for upcoming growth initiatives.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments, as the press release emphasizes strategic financing and asset development plans crucial for the company&#039;s growth trajectory.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>CNSP’s $22.5 million financing could boost investor confidence.</li><li>Strategic asset development may enhance long-term shareholder value.</li><li>Upcoming milestones could lead to significant price volatility.</li><li>CEO’s insights could influence market perception and demand for shares.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>CNS Pharmaceuticals participated in CEO Connect on May 20, 2026.</li><li>The company secured $22.5 million in financing.</li><li>CNSP focuses on developing therapies for serious diseases.</li><li>Key milestones are to be monitored by investors for future evaluations.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>CNSP&#039;s new financing positions it for growth; consider buying within the next quarter.</p>
  </section>
</section>


<p><i><strong>Access the CEO Connect segment </strong></i><a rel="nofollow" href="https://virtualinvestorco.com/cnsp/"><i><strong>here</strong></i></a></p> <p><strong id="dateline">HOUSTON, TX / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 20, 2026 / </strong>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CNSP">CNSP</a>) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a <a rel="nofollow" href="https://pr.report/lpm9">Virtual Investor CEO Connect Segment</a>.</p><p>As part of the segment, <a rel="nofollow" href="https://pr.report/lpma">Rami Levin, President and Chief Executive Officer</a> of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value. Additionally, Mr. Levin discussed the strategy for pipeline development and securing a new asset, key milestones investors should monitor to evaluate execution of the strategy and the Company's broader growth outlook and investment thesis moving forward.</p><p>The Virtual Investor CEO Connect segment is accessible <a rel="nofollow" href="https://pr.report/lpmb">here</a>.</p><p><strong>About CNS Pharmaceuticals, Inc.</strong></p><p>CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.</p><p>For more information, please visit <a rel="nofollow" href="https://pr.report/lpmc">www.CNSPharma.com</a>, and connect with the Company on <a rel="nofollow" href="https://pr.report/lpmd">X</a> and <a rel="nofollow" href="https://pr.report/lpme">LinkedIn</a>.</p><p><strong>Forward-Looking Statements</strong></p><p>Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.</p><p><strong>CONTACTS:</strong></p><p><strong>Investor Relations Contact</strong></p><p>JTC Team, LLC<br/>Jenene Thomas<br/>908.824.0775<br/><a rel="nofollow" href="mailto:CNSP@jtcir.com">CNSP@jtcir.com</a></p><p><strong>Business Development Contact</strong></p><p>CNS Pharmaceuticals, Inc.<br/>Dylan Wenke, Chief Business Officer<br/><a rel="nofollow" href="mailto:dwenke@cnspharma.com">dwenke@cnspharma.com</a></p><p><strong>SOURCE: </strong>CNS Pharmaceuticals, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cns-pharmaceuticals-ceo-rami-levin-participates-in-virtual-investor-c-1168479'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1168479" width="0" height="0"/>

CNS Pharmaceuticals participated in an investor segment, showcasing a recent $22.5 million financing that will enable new asset development. The CEO highlighted strategic initiatives aimed at long-term shareholder value, urging investors to track upcoming milestones indicative of growth.

cns-pharmaceuticals-ceo-rami-levin-participates-in-virtual-investor-ceo-connect-segment-highlighting-company-s-recent-strategic-transformation-progress

CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News